Up to £16 million available to grow UK capacity to manufacture viral vectors

Posted on: 27/10/2017

The latest in a suite of funding competitions supporting medicines manufacture via ISCF run by Innovate UK have been announced.

NEW: Innovate UK is to invest up to £16 million to grow the UK commercial capacity to manufacture viral vectors. This is to address the current and predicted shortfall in viral vector production and to increase UK competitiveness, productivity and better positioning the UK to manufacture viral vectors. These should be used in the development of clinical cell and gene therapies for the treatment of human disease and disorders.

This competition is not a collaborative R&D funded competition; it is for capital investment. The business must lead and can carry out the project on their own or in collaboration with others (businesses, RTOs, Catapults, charities or academia). To lead an application you must be a UK based business of any size, carry out your project in the UK and have a GMP manufacturing facility for viral vectors for advanced therapy medicinal products. Projects should range in size from total costs of £2 million to £6 million, and up to 100% funding is available.

To find out more, visit the funding page here.

Share this article